7 T	
AD	
* 112	

Award Number DAMD17-98-1-8301

TITLE: Androgen and Vitamin D Receptor Gene Polymorphisms and Breast Cancer Risk

PRINCIPAL INVESTIGATOR: John A. Baron, M.D.

CONTRACTING ORGANIZATION: Dartmouth College

Hanover, New Hampshire 03755-1404

REPORT DATE: October 1999

TYPE OF REPORT: Annual Summary

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

### REPORT DOCUMENTATION PAGE

Form Approved OMB No. 074-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503

1. AGENCY USE ONLY (Leave blank)	October 1999	Annual Summary			
4. TITLE AND SUBTITLE Androgen and Vitamin D R Breast Cancer Risk	eceptor Gene Polymory	phisms and	5. FUNDING NUDAMD17-98-		
6. AUTHOR(S) John A. Baron, M.D., M.S	•				
7. PERFORMING ORGANIZATION NAM Dartmouth College Hanover, New Hampshire 03755-14		8. PERFORMING ORGANIZATION REPORT NUMBER			
E-MAIL: john.a.baron@vixen.dartmouth.edu				NG / MONITORING	
9. SPONSORING / MONITORING AGENUS. Army Medical Research and Ma Fort Detrick, Maryland 21702-5012	ateriel Command			EPORT NUMBER	
12a. DISTRIBUTION / AVAILABILITY ST Approved for public rele		limited		12b. DISTRIBUTION CODE	
13. ABSTRACT (Maximum 200 Words) This project will assess polymorphisms of the and completed population-bas controls took part, provother life style factors be randomly selected for specimens for DNA has be of the AR and VDR on 300 controls who used HRT for incorporated into the estassociations with breast the administrative arran subject recruitment and epidemiology study is preshortly.	the association between and vitamin D and case-control study iding questionnaire of the control of the control of the cases and 300 control of the cancer risk will be gements for the work specimen accrual builtoned to the control of the control o	receptor among sure in Sweden. A to data regarding use opulation, 1800 costs. The collection sources; this actions who never use Information on the tabase, and odds computed. In the were established it. Recruitment	abjects in total of 3% se of exogo cases and is for the control of	a recently- 379 cases and 3527 enous hormones and 1800 controls will d or tissue or the measurement d 300 cases and 300 orphisms will be nmarizing the ear of the project, racking database for molecular	

NSN 7540-01-280-5500

**OF REPORT** 

17. SECURITY CLASSIFICATION

Unclassified

14. SUBJECT TERMS
Breast Cancer

Standard Form 298 (Rev. 2-89) Prescribed by ANSI Std. Z39-18 298-102

15. NUMBER OF PAGES

16. PRICE CODE

8

20. LIMITATION OF ABSTRACT

Unlimited

19. SECURITY CLASSIFICATION

Unclassified

**OF ABSTRACT** 

18. SECURITY CLASSIFICATION

Unclassified

**OF THIS PAGE** 

#### **FOREWORD**

Opinio	ons,	int	erpreta	ation	ns, d	conc:	lusions	and	recommenda	atio	ons a	are
those	of	the	author	and	are	not	necessa	arily	endorsed	by	the	U.S.
Army.												

\_\_\_ Where copyrighted material is quoted, permission has been obtained to use such material.

\_\_\_ Where material from documents designated for limited distribution is quoted, permission has been obtained to use the material.

\_\_\_ Citations of commercial organizations and trade names in this report do not constitute an official Department of Army endorsement or approval of the products or services of these organizations.

N/A In conducting research using animals, the investigator(s) adhered to the "Guide for the Care and Use of Laboratory Animals," prepared by the Committee on Care and use of Laboratory Animals of the Institute of Laboratory Resources, national Research Council (NIH Publication No. 86-23, Revised 1985).

 $\frac{N/A}{A}$  For the protection of human subjects, the investigator(s) adhered to policies of applicable Federal Law 45 CFR 46.

N/A In conducting research utilizing recombinant DNA technology, the investigator(s) adhered to current guidelines promulgated by the National Institutes of Health.

N/A In the conduct of research utilizing recombinant DNA, the investigator(s) adhered to the NIH Guidelines for Research Involving Recombinant DNA Molecules.

N/A In the conduct of research involving hazardous organisms, the investigator(s) adhered to the CDC-NIH Guide for Biosafety in Microbiological and Biomedical Laboratories.

PI - Signature

Date

## **Table of Contents**

Foreword	3
Introduction	5
Progress Narrative	5
Appendix I: List of Key Research Accomplishments	7
Appendix II: List of Reportable Outcomes	8

#### **Introduction**

This project aims to assess the association between the risk of breast cancer and polymorphisms of the androgen and vitamin D receptor genes (AR and VDR genes). This will be accomplished in the context of a recently-completed population-based case-control study in Sweden. A total 3879 cases and 3527 controls took part, providing questionnaire data regarding use of exogenous hormones, cigarette smoking, alcohol use, and other life style factors. From this study population, 1800 cases and 1800 controls will be randomly selected for genomic DNA analysis. The collection of blood or tissue specimens for DNA has been funded by other awards (from the National Institutes of Health and from the Army Medical Research and Materiel Command Breast Cancer Research Program). This award is for the measurement of the AR and VDR on 300 cases and 300 controls who never used HRT, and 300 cases and 300 controls who used HRT for 4 years or more. Information on these polymorphisms will be incorporated into the established subject database, and odds ratios summarizing the associations with breast cancer risk will be computed.

#### **Progress to Date**

Under previous funding, all questionnaire data have been obtained and organized, and several manuscripts dealing with the questionnaire data have been published:

- Magnusson C, Baron JA. Correia N, Bergstrom R, Adami HO, Persson I. Breast-cancer risk following long-term oestrogen- and oestrogen-progestin-replacement therapy. International Journal of Cancer. 81(3):339-44, 1999
- Magnusson CM, Persson IR, Baron JA, Ekbom A, Bergstrom R. Adami HO. The role of reproductive factors and use of oral contraceptives in the aetiology of breast cancer in women aged 50 to 74 years. International Journal of Cancer. 80(2):231-6, 1999.
- Magnusson C. Baron J, Persson I, Wolk A, Bergstrom R, Trichopoulos D, Adami HO. Body size in different periods of life and breast cancer risk in post-menopausal women. International Journal of Cancer. 76(1):29-34, 1998.

#### Administrative Preliminaries

The grantee organization, Dartmouth College, has established a subcontract with the Karolinska Institutet for the collaborative work described in our proposal. The Karolinska Institutet has an on-going relationship with investigators at Uppsala University in Uppsala, Sweden where most of the molecular analyses will be conducted.

### Recontacting study subjects to obtain germline DNA for analyses

This work, still in progress, has been funded by other awards from the National Institutes of Health and from the Army Medical Research and Materiel Command Breast Cancer Research Program. A substantial part of these efforts must be completed before the analyses funded in this project can proceed.

Recontact of cases and controls has proceeded in two phases. In phase I, 1198 subjects were selected. Of these, 918 agreed to donate blood, and 61 living subjects declined to give blood, but allowed use of tissue samples to obtain germline DNA, A further 171 subjects had died, but we will attempt to extract DNA from mastectomy and biopsy tissue samples. Thus we expect to obtain DNA from 1150 (96%) of the case selected. Seventeen further controls are considering whether to take part.

Of the 1112 controls chosen in phase I, 854 (77%) agreed to donate blood samples. 55 controls have died; without mastectomy/biopsy specimens to access, there is no readily available source of germline DNA for these subjects, or for the 228 control subjects who declined to give a blood specimen. To date, we have actually received blood specimens for 904 cases and 831 controls. Efforts continue to obtain blood on those who have agreed.

In the second phase of recruitment for the molecular studies, an additional 600 cases and 600 controls have been selected for recontact. We are in the process of sending out the letters to these women, and enter them into the process of obtaining blood specimens as in Phase I.

An administrative database has been constructed using MS Access to facilitate the in order to track the specimens and prepare for the incorporation of the laboratory results into the analysis database. This database allows us to track specimens in "real time," knowing where each subject stands in the process of recruitment, tissue retrieval and transshipment, and analysis. In addition, the system generates lists of patients to contact, mailing labels, letters, etc.

After being entered into the system, all blood/tissue specimens are sent to the molecular epidemiology laboratory in Uppsala, Sweden. DNA is being extracted, and the assays will begin shortly.

## Appendix I

## Key Research Accomplishments

- Completion of Organizational Prerequisites
- Construction of a Detailed Administrative Database
- Recruitment of Subjects to Molecular Epidemiology Study

# Appendix II

Reportable Outcomes:

(None)